A Phase 1/2 interventional study of Abiraterone acetate and Abiraterone acetate MTD in Prostatic Neoplasms, sponsored by Cougar Biotechnology, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-27.
Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 50th largest by enrollment, is the only one that started in 2005, is one of 8 in phase 1/2, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cougar Biotechnology, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Cougar Biotechnology, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 44th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2005, is one of 4 in phase 1/2, and was the 5th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).
This is an open-label (all people know the identity of the intervention) study to evaluate the safety, tolerability, and recommended dose of abiraterone acetate taken orally (by mouth), once daily in participants with HRPC. The study will consist of a dose escalation stage (Phase 1) that will be conducted to determine the MTD of abiraterone and an activity evaluation stage (Phase 2) to evaluate the activity of abiraterone in participants with HRPC. Escalated doses of abiraterone (starting at 250 milligram [mg] up to a maximum of 2000 mg) will be given for 28-day treatment periods to determine the MTD. Participants will be given MTD of abiraterone for up to 12 cycles (28 day each) in Phase 2 of the study. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
Drug: Abiraterone acetate · Drug: Abiraterone acetate MTD · Drug: Dexamethasone
Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
Also known as: CB7630
Abiraterone acetate MTD orally for 12 cycles (28 day each).
Also known as: CB7630
Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12
The PSA response was measured according to PSA working group (PSAWG) criteria. All participants achieving a fall in PSA of greater than 50 percent from baseline, which has been confirmed by a second measurement at least 4 weeks after initial documentation, fulfill criteria for confirmed PSA response.
Time frame: Baseline, Week 12
Number of Participants With Objective Tumor Response
Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.
Time frame: Baseline up to end of study (1160 days)
Duration of Prostate Specific Antigen (PSA) Response
Duration of PSA response in participants on abiraterone acetate therapy was measured as the duration between PSA 50 percent decline date and PSA progression date as defined by the PSAWG criteria.
Time frame: Baseline up to end of study (1160 days)
Duration of Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)
Number of participants with objective response based on assessment of confirmed CR or confirmed PR according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.
Time frame: Baseline up to end of study (1160 days)
Time to Disease Progression
Disease progression was defined as greater than 25 percent increase in sum of longest diameter of target lesions compared to baseline.
Time frame: Baseline up to end of study (1160 days)
Overall Survival
Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.
Time frame: Baseline up to end of study (1160 days)
Serum Blood Levels of Testosterone
Concentration of testosterone in blood was measured in nanogram per deciliter (ng/dL).
Time frame: Baseline, Cycle 2 (within 3 days prior to Day 29)
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 30 days after the last dose of study medication
Serum Blood Levels of Testosterone Precursors
Concentration of Cortisol, Aldosterone, Corticosterone, 11-Deoxycortisol, Deoxycorticosterone and Dehydroepiandrostenedione Sulphate (DHEA-S) in blood was measured in nanogram per deciliter (ng/dL).
Time frame: Baseline, Cycle 2 (within 3 days prior to Day 29)
Time to Prostate Cancer Pain Progression
The time from start of study treatment to the development/worsening of pain due to prostate cancer requiring one or more of the following treatments: 1- Opioid therapy (therapy with morphine like medicines for 10 out of 14 consecutive days); 2- Glucocorticoid therapy; 3- Initiation of \>= 5 mg of prednisolone for 10 out of 14 consecutive days; 4- Radionuclide therapy; 5- Radiation therapy (x-ray or cobalt treatment); 6- Chemotherapy (treatment of disease by chemical agents). Participants who do not experience prostate cancer pain were censored on their last day on study. Time to prostate cancer pain progression was measured by Kaplan-Meier method.
Time frame: Baseline up to 12 cycles
Number of Participants With Change From Baseline in Biochemical Bone Markers
Time frame: Baseline, Cycle 2, 4, 8, 12
Mean Plasma Concentration of Abiraterone
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Maximum Observed Plasma Concentration (Cmax) of Abiraterone
The Cmax is defined as maximum observed analyte concentration.
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone
The Tmax is defined as actual sampling time to reach maximum observed plasma concentration. The analyte concentration associated with Tmax is referred to as Cmax.
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Abiraterone
Area under the plasma concentration time-curve from time zero to the last quantifiable concentration (AUClast).
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Abiraterone
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Plasma Decay Half-Life (t1/2) of Abiraterone
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Time to Last Quantifiable Plasma Concentration (Tlast) of Abiraterone
The actual sampling time of last measurable (non-below the limit of quantification \[BQL\]) analyte concentration. The analyte concentration associated with Tlast is referred to as Clast.
Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
| Milestone | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day |
|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 42 | 3 |
| Completed | 2 | 2 | 3 | 25 | 2 |
| Not completed | 1 | 1 | 0 | 17 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 5 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 1 | 1 | 0 | 10 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
| Milestone | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day |
|---|---|---|---|---|---|
| Started | 1 | 2 | 2 | 23 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 2 | 23 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Disease progression | 0 | 2 | 2 | 17 | 1 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 3 | 0 |
The PSA response was measured according to PSA working group (PSAWG) criteria. All participants achieving a fall in PSA of greater than 50 percent from baseline, which has been confirmed by a second measurement at least 4 weeks after initial documentation, fulfill criteria for confirmed PSA response.
| Participants | 1000 mg AA Monotherapy | 1000 mg AA Therapy |
|---|---|---|
| Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12 | 10 | 25 |
Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.
| Participants | 1000 mg AA Therapy |
|---|---|
| Complete response | 0 |
| Partial response | 8 |
Duration of PSA response in participants on abiraterone acetate therapy was measured as the duration between PSA 50 percent decline date and PSA progression date as defined by the PSAWG criteria.
| Days | 1000 mg AA Therapy |
|---|---|
| Duration of Prostate Specific Antigen (PSA) Response | 141 (85 to 235) |
Number of participants with objective response based on assessment of confirmed CR or confirmed PR according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.
No measurements were reported for this outcome.
Disease progression was defined as greater than 25 percent increase in sum of longest diameter of target lesions compared to baseline.
No measurements were reported for this outcome.
Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.
No measurements were reported for this outcome.
Concentration of testosterone in blood was measured in nanogram per deciliter (ng/dL).
| ng/dL | 1000 mg AA Therapy |
|---|---|
| Baseline (n = 23) | 3 (1 to 10) |
| Cycle 2 (n = 28) | 1 (1 to 186) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day |
|---|---|---|---|---|---|
| AEs | 3 | 3 | 3 | 41 | 3 |
| SAEs | 2 | 2 | 0 | 20 | 2 |
Concentration of Cortisol, Aldosterone, Corticosterone, 11-Deoxycortisol, Deoxycorticosterone and Dehydroepiandrostenedione Sulphate (DHEA-S) in blood was measured in nanogram per deciliter (ng/dL).
| ng/dL | 1000 mg AA Therapy |
|---|---|
| Cortisol; Baseline (n = 33) | 12000 (7000 to 23000) |
| Cortisol; Cycle 2 (n = 29) | 4000 (1000 to 11000) |
| Aldosterone; Baseline (n=33) | 8 (1 to 32) |
| Aldosterone; Cycle 2 (n=29) | 8 (1 to 61) |
| Corticosterone; Baseline (n=33) | 193 (4 to 1041) |
| Corticosterone; Cycle 2 (n=27) | 6797 (12 to 17148) |
| 11-Deoxycortisol; Baseline (n=31) | 39 (20 to 233) |
| 11-Deoxycortisol; Cycle 2 (n=25) | 73 (20 to 836) |
| Deoxycorticosterone; Baseline (n=32) | 6 (2 to 31) |
| Deoxycorticosterone; Cycle 2 (n=28) | 121 (33 to 1627) |
| DHEA-S; Baseline (n=32) | 30000 (15000 to 176000) |
| DHEA-S; Cycle 2 (n=28) | 15000 (15000 to 15000) |
The time from start of study treatment to the development/worsening of pain due to prostate cancer requiring one or more of the following treatments: 1- Opioid therapy (therapy with morphine like medicines for 10 out of 14 consecutive days); 2- Glucocorticoid therapy; 3- Initiation of \>= 5 mg of prednisolone for 10 out of 14 consecutive days; 4- Radionuclide therapy; 5- Radiation therapy (x-ray or cobalt treatment); 6- Chemotherapy (treatment of disease by chemical agents). Participants who do not experience prostate cancer pain were censored on their last day on study. Time to prostate cancer pain progression was measured by Kaplan-Meier method.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
The Cmax is defined as maximum observed analyte concentration.
| nmol/L | Abiraterone Acetate 250 mg | Abiraterone Acetate 500 mg | Abiraterone Acetate 750 mg | Abiraterone Acetate 1000 mg | Abiraterone Acetate 2000 mg |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Abiraterone | 219 ± 172.77 | 284 ± 132.38 | 1032 ± 344.01 | 571 ± 443.18 | 531 ± 219.02 |
The Tmax is defined as actual sampling time to reach maximum observed plasma concentration. The analyte concentration associated with Tmax is referred to as Cmax.
| hours | Abiraterone Acetate 250 mg | Abiraterone Acetate 500 mg | Abiraterone Acetate 750 mg | Abiraterone Acetate 1000 mg | Abiraterone Acetate 2000 mg |
|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone | 2.050 ± 0.02 | 2.588 ± 1.02 | 1.709 ± 0.41 | 3.159 ± 1.79 | 2.672 ± 1.14 |
Area under the plasma concentration time-curve from time zero to the last quantifiable concentration (AUClast).
| hours*nmol/L | Abiraterone Acetate 250 mg | Abiraterone Acetate 500 mg | Abiraterone Acetate 750 mg | Abiraterone Acetate 1000 mg | Abiraterone Acetate 2000 mg |
|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Abiraterone | 1253 ± 519.78 | 1334 ± 731.47 | 4294 ± 1295.20 | 4371 ± 3427.54 | 4754 ± 1659.13 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| hours*nmol/L | Abiraterone Acetate 250 mg | Abiraterone Acetate 500 mg | Abiraterone Acetate 750 mg | Abiraterone Acetate 1000 mg | Abiraterone Acetate 2000 mg |
|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Abiraterone | 1369 ± 505.39 | 1448 ± 749.01 | 4537 ± 1333.42 | 4615 ± 3660.48 | 4983 ± 1755.24 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hour | Abiraterone Acetate 250 mg | Abiraterone Acetate 500 mg | Abiraterone Acetate 750 mg | Abiraterone Acetate 1000 mg | Abiraterone Acetate 2000 mg |
|---|---|---|---|---|---|
| Plasma Decay Half-Life (t1/2) of Abiraterone | 11.6 ± 10.14 | 9.5 ± 7.02 | 10.8 ± 5.91 | 10.6 ± 4.69 | 12.0 ± 2.29 |
The actual sampling time of last measurable (non-below the limit of quantification \[BQL\]) analyte concentration. The analyte concentration associated with Tlast is referred to as Clast.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 250 mg/Day | — | 2/3 (66.7%) | 3/3 (100%) |
| 500 mg/Day | — | 2/3 (66.7%) | 3/3 (100%) |
| 750 mg/Day | — | 0/3 (0%) | 3/3 (100%) |
| 1000 mg/Day | — | 20/42 (47.6%) | 41/42 (97.6%) |
| 2000 mg/Day | — | 2/3 (66.7%) | 3/3 (100%) |
| Event | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 0/3 | 1/42 | 0/3 |
| Oedema peripheralGeneral disorders | 0/3 | 0/3 | 0/3 | 0/42 | 1/3 |
| PainGeneral disorders | 1/3 | 0/3 | 0/3 | 0/42 | 0/3 |
| PyrexiaGeneral disorders | 0/3 | 1/3 | 0/3 | 1/42 | 0/3 |
| InfectionInfections and infestations | 0/3 | 1/3 | 0/3 | 0/42 | 0/3 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 1/3 | 0/3 | 0/3 | 0/42 | 0/3 |
| Lower respiratory tract infectionInfections and infestations | 1/3 | 0/3 | 0/3 | 1/42 | 0/3 |
| SepsisInfections and infestations | 0/3 | 1/3 | 0/3 | 2/42 | 0/3 |
| Urinary tract infectionInfections and infestations | 0/3 | 1/3 | 0/3 | 1/42 | 0/3 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 1/3 | 0/3 | 1/42 | 0/3 |
| Event | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/3 | 0/3 | 2/3 | 5/42 | 1/3 |
| Oedema peripheralGeneral disorders | 0/3 | 0/3 | 1/3 | 19/42 | 3/3 |
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 2/3 | 3/3 | 34/42 | 1/3 |
| ConstipationGastrointestinal disorders | 2/3 | 0/3 | 1/3 | 11/42 | 0/3 |
| VomitingGastrointestinal disorders | 2/3 | 0/3 | 1/3 | 8/42 | 1/3 |
| FatigueGeneral disorders | 2/3 | 1/3 | 2/3 | 21/42 | 2/3 |
| Pitting oedemaGeneral disorders | 0/3 | 0/3 | 0/3 | 2/42 | 2/3 |
| AnorexiaMetabolism and nutrition disorders | 0/3 | 2/3 | 1/3 | 3/42 | 0/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 2/3 | 12/42 | 0/3 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 2/3 | 8/42 | 0/3 |
| Age, Continuous(years) | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day | Total |
|---|---|---|---|---|---|---|
| Mean | 61.3 ± 9.07 | 68.7 ± 10.41 | 76 ± 8.19 | 70.4 ± 7.42 | 68 ± 12.17 | 69.9 ± 8.04 |
| Sex: Female, Male(Participants) | 250 mg/Day | 500 mg/Day | 750 mg/Day | 1000 mg/Day | 2000 mg/Day | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 3 | 3 | 42 | 3 | 54 |
The record gives a start of Nov 2005, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate